• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Consumer Staples

A Growth Story With Years of Value

Neogen, a food-safety company, serves an essential need for some very large customers
By SHAM GAD Jan 19, 2012 | 04:00 PM EST
Stocks quotes in this article: CMG, NEOG, KFT, KO, MCD, BCPC

I'm not usually a fan of stocks that trade for 30x earnings and over 25x free cash flow. Such a scenario creates a huge reliance on growth. But one of the most valuable lessons an investor can learn is to look beyond the first layer of a company -- its valuation metrics -- and see what the story is all about.

I missed Chipotle Mexican Grill (CMG) when it was trading at $150 a share, because of a price-to-earnings ratio of 33 several years back, despite my deep familiarity with the company's story and how rapidly the business was growing. Owing Chipotle several years back at 30x earnings translates into owning the company today at less than 20x earnings, on the basis of that past price. 

While it is certainly no Chipotle, Neogen (NEOG) is a business that appears to be sitting on the bottom half of its growth curve. Shares currently trade for $32, down from $48, implying a market cap of $750 million. For fiscal 2011, ended May 31, 2011, revenue was $172 million, of which $23 million hit the bottom line. For the first six months of fiscal 2012, revenue totaled $90 million, and net income was $11.2 million. For this small-cap, the fiscal 2012 quarterly numbers represent the 75th consecutive profitable quarter from operations and the 79th quarter out of 84 that Neogen has reported a revenue increase from a year earlier.

Despite this company's fancy tech-sounding like name, it is actually is a very simple business: the development and sale of food and animal safety products. The company makes and markets diagnostic tests for food processors, drug detection for livestock, vaccines and animal care products. From the farm to the dining room table, Neogen provides service to food producers and processors at every point of the food chain. Its two divisions, animal safety and food safety, each account for about half of the company's revenue. 

For customers of Neogen, its products are non-discretionary expenses. The economic and legal costs of a food illness or animal contamination are far too high to risk not being protected. In most cases, law dictates that proper food and animal testing occur before it can be sold or consumed by the public. According to the U.S. Centers for Disease Control and Prevention, every year, 1 in 6 Americans gets food poisoning, or nearly 50 million people. Of that number, 128,000 are hospitalized, and 3,000 die. 

Neogen operates in markets that offer significant room for growth. The intervention products market, which includes vaccines, diagnostic tests, pharmaceuticals and veterinarians' instruments, is a $21 billion market, and Neogen currently markets products in each of those segments. The company serves the world's largest food producers and processors, including Kraft (KFT), McDonald's (MCD) and Coca-Cola (KO). For these customers, the money they spend with Neogen is a minuscule fraction of their expense, but it is an essential expense. That gives Neogen a slight degree of pricing power, and its gross margins exceed 50%. 

True comparable companies are hard to find, but Balchem (BCPC) seems like the lone standout. Balchem is valued at $1.2 billion and has an enterprise value of $1.1 billion, a trailing P/E of 31 and a multiple of 16x EV/EBITDA. Balchem has annual revenue of about $300 million, with operating margins of 19% and a return on equity of 19%. Those multiples are very close to those of Neogen, and Balchem has been a consistent performer for years.

Yet Neogen gets very little coverage, even though it is just the type of business one would like to own in any economy, especially this one. It's a very asset-light business, with only $22 million in property, plant and equipment and $31 million in inventory. The company has very low annual capital expenditure, as cash has grown from $14 million in fiscal 2009 to over $36 million in fiscal 2011. Since 2000, Neogen has made over $80 million in acquisitions, all of which were financed with cash on hand, which represent over $60 million in annual sales. As that trend continues, it will add another lever for growth. 

Neogen is a fantastic business, and the market seems to get that. It's highly unlikely that you will ever get a chance to own this business at a dirt-cheap valuation multiple. Given the company's significant growth potential and the high probability that such growth will continue for many years, the valuation doesn't deserve to get that low in this low-growth economy. Growth will be the company's value-creating catalyst. While I am not pulling the trigger at these prices, this is a fantastic business run by a quality management team, and it is sitting at the top of my watch list.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gad had no positions in stocks mentioned.

TAGS: Investing | U.S. Equity | Consumer Staples | Healthcare

More from Consumer Staples

My Top Stock Pick for 2021

Ed Ponsi
Dec 31, 2020 8:30 AM EST

Even after a solid 2020, this company has laid the groundwork for a successful 2021.

With Dividend Investing En Vogue, Here Are 4 More Stocks to Consider

Chris Versace
Dec 22, 2020 10:00 AM EST

The consistent annual dividend increases by this quartet even during bad times make them good income-investing bets going forward.

2 Food Stocks Worth Digging Into for Dividend-Hungry Investors

Chris Versace
Dec 3, 2020 11:00 AM EST

Long histories of annual dividend increases make Hormel Foods and McCormick & Co. attractive income plays.

Snack Maker Utz Brands Could Be a Stock to Dip Into Based on Its Charts

Bruce Kamich
Nov 24, 2020 8:42 AM EST

There is a limited price history with the company, which went public in August, but aggressive traders could probe its long side.

Pandemic Should Help This Cereal Maker Remain a Serial Dividend Payer

Chris Versace
Sep 27, 2020 8:15 AM EDT

Food company General Mills is benefiting as more consumers work from home and dine out less.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login